A Study of Efficacy and Safety of AND017 in Patients With Myelodysplastic Syndrome

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2024
This is a Phase 2, multicenter, randomized, open-lable study to evaluate the efficacy and safety of luspatercept (ACE-536) for the treatment of anemia due to lower risk Myelodysplastic syndromes (MDS)in patients subjects who are Red blood cell (RBC) non-transfusion dependent (NTD) and low transfusion burden (LTB).
Epistemonikos ID: 72eb3a48a799721a3a8ab6a395acf0fdb38b163a
First added on: May 15, 2024